

VALUE FOCUS

Medical Technology



Mid-Year 2014


Macro Trends	1
Public Market Trends and Outlook	2
M&A Trends	4
Appendix: Publicly Traded Medical Technology Companies	5
About Mercer Capital	11

Macro Trends

Medical technology industry performance is heavily tied to the overall healthcare sector as it provides many of the inputs that go into the management, optimization, technology, and other tools used by physicians and healthcare practitioners. From a macro perspective there are a few key trends that medical technology companies could take advantage of which highlight overall growth and development of the healthcare sector.

Aging of the Population


As more Americans reach retirement age, retirees will constitute a larger portion of the overall population. Additionally, with the impacts of the Affordable Care Act coming into effect, individuals who were previously uninsured will enter the market. About 19% of new Medicaid enrollees were older than 54, six percentage points above the Urban Institute's expectations, according to Molina Healthcare. This adds as many as 1.3 million patients who may get elective procedures that were put off while uninsured.



Source: US Bureau of the Census

Rising Healthcare Spending

The US Centers for Disease Control and Prevention has projected national healthcare expenditures to exceed \$3 trillion at year-end 2014 and to exceed \$5 trillion by 2021. Current spending accounts for approximately 17.5% of GDP and is projected to approach 19.5% by 2021.




Source: US Center for Disease Control

Public Market Trends and Outlook

The medical technology industry consists of a diverse group of companies working in several different segments. For the purpose of this report, we have categorized the industry into five key segments consisting of Biotechnology, Healthcare Technology, Healthcare Supplies, Medical Equipment, and Life Science Tools and Services companies.¹

Medtech Returns Outpacing the Broader Market

The S&P 500 Healthcare Sector Index consists of top companies within the sector, including companies within the medical technology industry and the sector has outperformed the overall equity market, since mid-year 2010. Like the healthcare sector, the medical technology industry has also produced higher returns than the overall market, as highlighted by the segment index performance shown below. Excluding the health supplies and equipment segments, all of the other medical technology segment indices produced higher returns than the S&P 500, with the biotechnology and healthcare technology segments significantly outperforming the overall market.



Source: S&P Capital IQ

¹ *Biotechnology* includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering.

Healthcare Technology includes companies providing information technology services primarily to healthcare providers. The healthcare technology segment includes companies providing application, systems and/or data processing software, internet-based tools, and IT consulting services to doctors; hospitals or businesses operating primarily in the healthcare sector.

Healthcare Supplies consists of manufacturers of healthcare supplies and medical products not classified elsewhere. The healthcare supplies segment includes eye care products, hospital supplies, and safety needle and syringe devices.

Medical Equipment includes manufacturers of healthcare equipment and devices.

Life Science Tools and Services includes companies enabling the drug discovery, development, and production continuum by providing analytical tools, instruments, consumables and supplies, clinical trial services, and contract research services.

Public Market Trends and Outlook (cont.)

Medtech Industry Multiples

Overall industry multiples highlight favorable trends and outlook for the sector. As, forward price-to-earnings multiples exceeded 19x across all industry segments. Additionally median revenue growth in the last twelve month period was approximately 6.2%. Further industry performance is outlined by segment in the appendix.

Segment	EV/ Revenue	EV/ EBITDA	LTM Revenue	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
Biotechnology	8.9	20.4	439	301	21.9	31.7%	32.4%
Healthcare Technology	3.7	17.4	407	57	26.7	8.8%	8.6%
Healthcare Supplies	3.6	14.0	397	70	22.2	8.3%	10.3%
Medical Equipment	3.4	13.7	953	210	19.9	4.6%	1.2%
Life Science Tools and Services	2.6	14.2	1,904	291	21.5	6.3%	11.6%
Medtech Industry	3.8	14.5	687	169	21.8	8.6%	9.8%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Segment Outlooks

Significant events and key developments from the six-month period ending June 30, 2014, are presented below.

- Biotechnology.** The performance of the biotech segment in the next few years may be underpinned by the strong fundamentals of mature and profitable growth within biotech peer groups, which account for approximately half of the Nasdaq Index weighting. Segment projections call for a near doubling of revenue for these groups by 2018, with aggregate sales topping \$100 billion. Net income is expected to grow 127% by 2018 to \$47 billion, with \$41 billion coming from the mature biotechs alone.
- Healthcare Technology.** This segment has seen a boost between the more recent emphasis on data and analytics availability and increased cyber security concerns. The breach of Community Health's network, which compromised nonmedical information from 4.5 million patients, may have exposed the need for hospitals to increase spending on data security. Providers and payers may spend \$11.5 billion a year on electronic health records by 2018, according to IDC. This effort heightens the need to secure data networks given that sensitive patient records will be shared electronically across all health-care services.
- Healthcare Supplies.** Healthcare supply companies have had to adjust to changes in customer purchasing power. Many physicians now work for hospitals or group practices that are aligned with larger medical centers, leaving individual physicians or small private practices with less and less influence, due to these structural shifts. In turn, hospitals acting as "economic buyers" use their purchasing influence to drive down costs, thus impacting suppliers' margins.
- Medical Equipment.** Medical equipment earnings are centered on procedure volumes and new product launches. Innovations such as Medtronic's transcatheter heart valve may increase heart valve revenue growth as new patients are treated. Orthopedic demand may rise given the aging population and expansion of covered patients by the Affordable Care Act. Cardiovascular procedures may increase modestly. Boston Scientific may continue to gain stent market share with its smaller Promus Premier device.
- Life Science Tools and Services.** With greater emphasis on data analytics in pharmaceutical development, more and more information technology companies, that may or may not have previously operated in the healthcare sector are investing to expand operations in the life science segment. The more life science companies continue to merge operating and analytical technologies into R&D processes, development will continue to be streamlined. Within the segment, laboratories in particular are always looking for improved cost and performance in equipment. As lab instruments improve and provide larger and more complex data sets, appropriate informatics and analytic technologies will be crucial.


M&A Trends

Medical equipment M&A is expected to increase as the number of new products being introduced expands the treatable patient populations, thus allowing companies to evaluate new synergistic opportunities. Also, valuations continue to remain low in the medical equipment segment; current price-to-sales multiples for growth companies are close to their five-year lows and interest rates remain low. Multiples have fallen for Edwards Lifesciences, Volcano and NuVasive due to weak U.S. reimbursement and increased competition, while HeartWare has fallen due to stroke risks for its HVAD. These companies fit the criteria of large makers of innovative devices that treat unmet medical needs, generating high sales growth.

The biotech segment represents a core drug discovery engine for the pharma industry, enticing competitive licensing deals and M&A. Large companies are particularly keen to bring in new assets, using deals as a way to bolster pipelines. Generous premiums often trigger reassessment of drug asset values across the entire area. As exemplified by the recent M&A announcement from Idenix, an early-stage biotech with innovative platforms can be particularly in demand.

Total medtech M&A deal values came to \$30 billion in the first half of 2014, an increase of 363% on the \$7 billion in the first half of 2013. Despite the growth in deal value, the number of overall deals actually fell by 10% in this period. The increase in 2014 from 2013 was largely due to the major acquisitions of Life Technologies by Thermo-Fisher for \$13.6 billion and J&J's Ortho-Clinical Diagnostics unit by The Carlyle Group for \$4.2 billion. The ongoing Medtronic-Covidien and Zimmer-Biomet mergers, though, will dwarf these earlier acquisitions. Worth \$42.9 billion and \$13.4 billion, respectively as of June 2014, these deals will change the face of the medtech industry.

Through the first half of 2014, there were 86 disclosed deals. As shown by the chart to the right, the majority of deals had a total deal value less than \$100 million with the average deal value being approximately \$442 million. Stryker Corporation was one of the most active investors during year to date, with four acquisitions. In the first half of the year, Thermo Fisher Scientific Inc. led all transaction sizes with an acquisition deal valued greater than \$16 billion.



Source: S&P Capital IQ

Selected Medical Technology Mergers and Acquisitions

First Half of 2014

Buyer	Target	Industry Segment	Date Closed	Total Trans. Value (USD mm)	Implied EV/ EBITDA
Valeant Pharmaceuticals International, Inc.	Solta Medical, Inc.	Healthcare Equipment	1/23/14	279	110.6
Thermo Fisher Scientific, Inc.	Life Technologies Corporation	Life Sciences Tools and Services	2/3/14	16,019	13.1
JLL Partners; Koninklijke DSM N.V.	Patheon Inc.	Life Sciences Tools and Services	3/11/14	1,922	14.5
EKF Diagnostics Holdings	Separation Technology Inc.	Healthcare Equipment	3/12/14	4	8.0
Stryker Corporation	Patient Safety Technologies, Inc.	Healthcare Equipment	3/24/14	113	35.2
Smith & Nephew, Inc.	ArthroCare Corporation	Healthcare Equipment	5/29/14	1,730	17.8
Repligen Corporation	Refine Technology, LLC	Life Sciences Tools and Services	6/2/14	33	17.6
Average				2,871	31.0
Median				279	17.6

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Biotechnology

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
Gilead Sciences Inc.	GILD	82.91	84.88	97.7%	127,323	0.71	7.5	12.5	17,437	10,496	11.9	69.1%	125.2%
Amgen Inc.	AMGN	118.37	128.96	91.8%	89,609	0.62	5.2	12.5	19,460	8,134	14.1	10.2%	14.5%
Biogen Idec Inc.	BIIB	315.31	358.89	87.9%	74,792	1.19	8.9	20.4	8,345	3,641	25.4	40.4%	44.9%
Celgene Corporation	CELG	85.88	87.37	98.3%	68,776	1.14	9.8	28.5	7,033	2,416	21.9	18.6%	-3.4%
Regeneron Pharmaceuticals, Inc.	REGN	282.47	352.49	80.1%	28,344	0.98	11.3	31.2	2,499	904	26.9	43.6%	29.6%
Alexion Pharmaceuticals, Inc.	ALXN	156.25	185.43	84.3%	30,906	0.63	15.3	37.8	1,921	779	34.0	45.2%	54.3%
Pharmacyclics Inc.	PCYC	89.71	154.89	57.9%	6,731	0.72	13.9	49.0	435	123	NM	99.4%	52.9%
United Therapeutics Corporation	UTHR	88.49	116.65	75.9%	4,245	1.34	3.1	7.6	1,203	499	10.6	19.1%	10.0%
Myriad Genetics Inc.	MYGN	38.92	42.50	91.6%	2,912	0.78	3.5	9.0	778	301	19.6	26.9%	26.2%
Acorda Therapeutics, Inc.	ACOR	33.71	39.95	84.4%	1,407	1.17	3.2	24.1	355	47	31.0	11.7%	95.0%
PDL BioPharma, Inc.	PDLI	9.68	10.21	94.9%	1,555	0.28	4.0	4.0	439	435	6.0	8.0%	14.5%
INSYS Therapeutics, Inc.	INSY	31.23	57.91	53.9%	1,069	1.83	6.1	18.1	167	56	22.6	319.0%	6226.9%
Anacor Pharmaceuticals, Inc.	ANAC	17.73	23.07	76.9%	743	1.43	33.3	-9.5	19	(67)	NM	76.1%	32.4%
Ligand Pharmaceuticals Incorporated	LGND	62.29	80.42	77.5%	1,291	1.25	23.4	65.6	54	19	55.3	31.7%	59.5%
Emergent BioSolutions, Inc.	EBS	22.46	28.48	78.9%	840	1.00	2.6	14.6	351	64	21.8	22.6%	27.8%
Enanta Pharmaceuticals, Inc.	ENTA	43.07	46.44	92.7%	798	0.00	15.2	35.4	46	20	5.5	42.7%	102.9%
Repligen Corporation	RGEN	22.79	23.14	98.5%	730	1.12	10.0	26.8	66	25	72.1	-2.7%	4.0%
Average		88.31	107.16	83.7%	26,004	0.95	10.4	22.8	3,565	1,641	25.2	51.9%	406.9%
Median		62.29	80.42	84.4%	2,912	1.00	8.9	20.4	439	301	21.9	31.7%	32.4%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Healthcare Technology

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
Quality Systems Inc.	QSII	16.05	24.15	66.5%	967	0.71	1.9	17.0	453	50	26.7	0.3%	-47.9%
Veeva Systems Inc.	VEEV	25.45	49.00	51.9%	3,252	0.00	12.4	63.7	234	46	92.0	58.3%	34.1%
Computer Programs & Systems Inc.	CPSI	63.60	71.89	88.5%	710	0.48	3.4	12.0	203	57	19.2	3.7%	16.0%
Simulations Plus, Inc.	SLP	5.62	7.09	79.3%	91	0.41	7.4	18.1	11	4	23.9	8.8%	8.6%
Omnicell, Inc.	OMCL	28.71	30.33	94.7%	1,051	0.90	2.3	15.8	407	60	23.0	14.4%	18.6%
MedAssets, Inc.	MDAS	22.84	26.58	85.9%	1,393	1.05	3.2	10.7	683	203	16.2	1.8%	-4.2%
Cerner Corporation	CERN	51.58	63.07	81.8%	17,711	0.62	5.5	20.9	3,075	806	30.0	13.4%	3.1%
HMS Holdings Corp.	HMSY	20.41	26.77	76.2%	1,789	0.35	4.1	17.4	467	110	35.5	-4.5%	-22.1%
Healthstream Inc.	HSTM	24.30	39.77	61.1%	670	1.40	3.7	22.9	152	25	72.2	30.9%	10.7%
Average		28.73	37.63	76.2%	3,070	0.66	4.9	22.1	632	151	37.6	14.1%	1.9%
Median		24.30	30.33	79.3%	1,051	0.62	3.7	17.4	407	57	26.7	8.8%	8.6%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Medical Supplies

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
The Cooper Companies Inc.	COO	135.53	145.34	93.3%	6,497	0.34	4.1	14.3	1,641	474	18.1	6.7%	9.6%
DENTSPLY International Inc.	XRAY	47.35	50.99	92.9%	6,714	1.26	2.8	14.2	2,953	577	18.4	0.4%	4.8%
Align Technology Inc.	ALGN	56.04	65.10	86.1%	4,575	1.81	5.9	20.8	712	202	30.9	20.4%	40.1%
West Pharmaceutical Services, Inc.	WST	42.18	51.12	82.5%	2,981	0.75	2.2	12.0	1,400	262	21.6	7.0%	14.8%
Haemonetics Corporation	HAE	35.28	45.90	76.9%	1,816	0.72	2.2	17.6	943	117	18.7	0.9%	-38.4%
Neogen Corp.	NEOG	40.47	51.25	79.0%	1,484	1.03	5.7	26.9	247	53	45.2	19.2%	9.3%
ICU Medical, Inc.	ICUI	60.81	85.00	71.5%	925	0.46	2.0	9.1	311	69	46.0	-1.9%	-12.6%
Meridian Bioscience, Inc.	VIVO	20.64	27.72	74.5%	858	1.27	4.3	13.8	191	59	22.1	4.6%	-4.0%
ATRION Corp.	ATRI	326.00	337.25	96.7%	642	0.77	4.4	12.3	137	49	22.3	9.7%	11.1%
Merit Medical Systems, Inc.	MMSI	15.10	17.08	88.4%	649	0.77	1.8	12.3	483	72	18.7	17.3%	34.6%
Anika Therapeutics Inc.	ANIK	46.33	52.49	88.3%	638	1.76	5.6	8.9	99	62	29.9	35.2%	95.1%
Vascular Solutions Inc.	VASC	22.19	28.21	78.7%	380	0.09	3.0	14.4	116	24	27.9	13.3%	20.3%
Average		70.66	79.79	84.0%	2,347	0.92	3.7	14.7	770	168	26.6	11.1%	15.4%
Median		44.26	51.19	84.3%	1,204	0.77	3.6	14.0	397	70	22.2	8.3%	10.3%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Medical Equipment

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
Intuitive Surgical, Inc.	ISRG	411.80	541.23	76.1%	15,815	1.04	6.9	19.5	2,052	732	32.5	-12.2%	-26.3%
Zimmer Holdings, Inc.	ZMH	103.86	108.33	95.9%	17,430	0.99	3.8	10.3	4,659	1,703	17.0	3.2%	2.2%
CareFusion Corporation	CFN	44.35	44.68	99.3%	9,194	0.93	2.4	10.9	3,842	861	16.8	8.2%	-0.1%
CR Bard Inc.	BCR	143.01	150.13	95.3%	10,906	0.70	3.6	13.7	3,146	829	18.4	5.4%	-6.3%
Edwards Lifesciences Corp.	EW	85.84	88.19	97.3%	9,056	0.50	4.2	17.9	2,129	500	26.3	8.0%	-4.9%
Varian Medical Systems, Inc.	VAR	83.14	86.60	96.0%	8,643	0.88	2.7	12.3	3,008	659	18.1	2.7%	-4.3%
ResMed Inc.	RMD	50.63	57.34	88.3%	7,105	0.77	4.2	13.5	1,555	485	19.4	2.7%	5.9%
Sirona Dental Systems Inc.	SIRO	82.46	82.84	99.5%	4,754	1.38	3.9	15.9	1,160	287	21.5	8.4%	5.7%
Teleflex Incorporated	TFX	105.60	109.73	96.2%	4,368	0.99	3.0	13.6	1,759	385	18.3	9.0%	18.4%
Steris Corp.	STE	53.48	55.36	96.6%	3,168	1.09	2.1	11.2	1,660	313	18.7	8.3%	5.0%
Hill-Rom Holdings, Inc.	HRC	41.51	44.64	93.0%	2,375	1.37	1.6	9.7	1,644	267	17.1	-3.8%	-3.4%
Globus Medical, Inc.	GMED	23.92	27.14	88.2%	2,250	0.00	4.4	12.8	450	154	25.1	10.5%	14.5%
Thoratec Corp.	THOR	34.86	43.58	80.0%	1,983	0.83	3.1	12.9	498	121	19.2	14.5%	16.9%
Cyberonics Inc.	CYBX	62.46	73.52	85.0%	1,666	0.68	6.0	18.1	282	93	26.5	0.8%	-9.6%
Masimo Corporation	MASI	23.60	32.20	73.3%	1,339	0.73	2.8	16.0	545	96	18.6	10.9%	12.1%
Greatbatch, Inc.	GB	49.06	50.17	97.8%	1,221	1.01	1.8	10.4	690	118	20.4	3.9%	-1.1%
Abaxis, Inc.	ABAX	44.31	51.84	85.5%	995	1.16	7.8	43.9	176	31	48.6	7.8%	5.0%
CONMED Corporation	CNMD	44.15	50.47	87.5%	1,202	1.32	1.2	7.2	747	125	22.5	-5.9%	0.1%
Natus Medical Inc.	BABY	25.14	27.71	90.7%	791	1.16	4.0	23.3	348	60	20.6	-1.7%	-2.2%
ABIOMED, Inc.	ABMD	25.14	30.77	81.7%	988	1.53	4.0	67.6	190	11	38.5	2.4%	46.8%
Analogic Corporation	ALOG	78.24	99.97	78.3%	968	0.80	1.7	14.3	542	64	17.7	17.1%	-20.4%
AngioDynamics Inc.	ANGO	16.33	19.00	85.9%	576	0.73	2.4	18.5	351	46	25.0	1.2%	5.2%
Average		74.22	85.25	89.4%	4,854	0.94	3.5	17.9	1,429	361	23.0	4.6%	2.7%
Median		49.85	53.60	89.5%	2,313	0.96	3.4	13.7	953	210	19.9	4.6%	1.2%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Life Science Tools & Services

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
Thermo Fisher Scientific, Inc.	TMO	118.00	127.63	92.5%	47,075	0.94	4.2	19.0	14,884	3,318	16.3	16.5%	23.9%
Illumina Inc.	ILMN	178.54	183.30	97.4%	22,925	0.56	14.1	49.7	1,612	457	79.1	26.7%	20.7%
Waters Corporation	WAT	104.44	115.06	90.8%	8,855	0.84	4.3	14.0	1,935	596	18.8	4.4%	2.1%
Mettler-Toledo International Inc.	MTD	253.18	258.31	98.0%	7,398	1.09	3.2	15.6	2,435	497	21.0	4.1%	4.9%
PerkinElmer Inc.	PKI	46.84	47.64	98.3%	5,303	0.89	2.7	14.5	2,209	414	18.4	3.9%	28.0%
Covance Inc.	CVD	85.58	106.50	80.4%	4,914	0.91	1.8	11.2	2,489	402	21.7	9.2%	22.2%
Techne Corp.	TECH	92.57	96.96	95.5%	3,425	0.61	9.0	17.4	357	184	26.1	15.1%	6.7%
PAREXEL International Corporation	PRXL	52.84	57.25	92.3%	3,005	0.93	1.5	10.7	1,939	281	21.2	11.8%	35.1%
Bio-Rad Laboratories, Inc.	BIO	119.71	134.13	89.2%	3,469	1.19	1.5	10.8	2,154	301	27.3	2.7%	-21.3%
Bruker Corporation	BRKR	24.27	24.93	97.4%	4,074	1.22	2.1	16.0	1,872	249	26.5	3.2%	1.2%
Charles River Laboratories International, Inc.	CRL	53.52	62.50	85.6%	2,589	0.90	2.5	11.3	1,222	272	16.5	6.9%	9.0%
Luminex Corporation	LMNX	17.15	24.10	71.2%	729	0.55	3.0	17.9	218	36	31.3	2.4%	5.4%
Albany Molecular Research Inc.	AMRI	20.12	20.55	97.9%	651	1.75	2.4	13.0	255	47	22.1	5.7%	14.1%
Cambrex Corporation.	CBM	20.70	22.34	92.7%	634	0.73	2.0	9.7	345	69	17.7	29.0%	35.6%
Average		84.82	91.51	91.4%	8,218	0.94	3.9	16.5	2,423	509	26.0	10.1%	13.4%
Median		69.55	79.73	92.6%	3,772	0.90	2.6	14.2	1,904	291	21.5	6.3%	11.6%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Appendix: Publicly Traded Medical Technology Companies

Conglomerate Companies

Company Name	Ticker	Price at 6/30/14	High Price 6/30/14	% of High 6/30/14	Market Cap (millions) 6/30/14	5 Year Beta	EV/Rev.	EV/ EBITDA	LTM Rev.	LTM EBITDA	Forward P/E	Revenue Growth (from LTM)	EBITDA Growth (from LTM)
3M	MMM	143.24	145.53	98.4%	93,719	1.15	3.1	11.8	31,450	8,298	18.7	3.9%	6.5%
Abbott Laboratories	ABT	40.90	41.30	99.0%	61,429	0.35	2.8	13.5	21,883	4,618	17.8	5.6%	8.8%
Agilent Technologies	A	57.44	61.22	93.8%	19,143	1.68	2.8	14.1	6,780	1,337	17.5	-1.8%	-4.3%
Allergan	AGN	169.22	174.49	97.0%	50,353	0.80	7.2	21.7	6,745	2,250	28.3	14.2%	15.5%
Baxter International	Bax	72.30	75.88	95.3%	39,110	0.73	2.8	11.1	16,326	4,126	13.9	15.3%	6.3%
Corning Life Sciences	GLW	21.95	22.20	98.9%	28,721	1.65	3.3	10.7	8,794	2,721	13.8	10.2%	12.0%
Danaher	DHR	78.73	81.14	97.0%	55,074	1.08	2.8	12.9	19,562	4,297	20.5	5.3%	6.8%
Endo Health Solutions	ENDP	70.02	82.16	85.2%	10,662	1.22	5.3	17.0	2,560	794	18.3	-5.6%	-26.9%
General Electric	GE	26.28	28.09	93.6%	263,530	1.48	4.4	22.6	146,124	28,281	15.4	0.4%	-4.4%
Hospira	HSP	51.37	52.86	97.2%	8,586	0.58	2.3	16.5	4,279	588	23.6	6.9%	132.2%
IDEX	IDXX	133.57	136.13	98.1%	6,853	0.74	4.9	21.0	1,443	335	33.8	9.3%	4.7%
Johnson & Johnson	JNJ	104.62	106.00	98.7%	295,980	0.59	3.9	11.6	73,540	24,506	17.6	5.1%	9.2%
Kimberly-Clark	KMB	111.22	113.93	97.6%	41,907	0.23	2.3	11.6	21,188	4,116	17.8	0.2%	-4.5%
Pall	PLL	85.39	91.83	93.0%	9,366	1.40	3.4	15.5	2,706	597	22.7	2.0%	-6.8%
Stryker	SYK	84.32	86.93	97.0%	31,965	0.89	3.3	21.9	9,287	1,413	17.0	5.6%	-26.6%
Boston Scientific Corporation	BSX	12.77	14.08	90.7%	16,891	1.09	2.9	12.8	7,220	1,631	15.7	1.3%	0.1%
Becton Dickinson	BDX	118.30	120.66	98.0%	22,856	0.78	2.9	11.1	8,291	2,173	18.1	4.7%	4.2%
Medtronic	MDT	63.76	65.50	97.3%	63,517	1.05	3.6	11.0	16,893	5,575	15.8	2.0%	1.4%
Average		80.30	83.33	95.9%	62,203	0.97	3.6	14.9	22,504	5,425	19.2	4.7%	7.5%
Median		75.52	81.65	97.1%	35,537	0.97	3.2	13.2	9,041	2,485	17.8	4.9%	4.4%

Pricing as of June 30, 2014

Source: S&P Capital IQ

Mercer Capital

Medical Technology Industry Services

Mercer Capital has expertise providing business valuation and financial advisory services to companies in the medical technology industry.

Industry Segments

Mercer Capital serves the following industry segments:

- Biotechnology
- Healthcare Technology
- Healthcare Supplies
- Medical Equipment
- Life Science Tools & Services

Services Provided

- Valuation of medical technology companies
- Transaction advisory for acquisitions and divestitures
- Valuations for purchase accounting and impairment testing
- Fairness and solvency opinions
- Litigation support for economic damages and valuation and shareholder disputes

Contact a Mercer Capital professional to discuss your needs in confidence.

Contact Us

Jay D. Wilson, Jr., CFA, ASA, CBA
901.322.9725
wilsonj@mercercapital.com

Timothy R. Lee, ASA
901.322.9740
leet@mercercapital.com

Sujan Rajbhandary, CFA
901.322.9749
sujanr@mercercapital.com

Demitri E. Jerow
901.322.9727
jerowd@mercercapital.com

Mercer Capital
5100 Poplar Avenue, Suite 2600
Memphis, Tennessee 38137
901.685.2120 (P)

www.mercercapital.com